These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9387515)

  • 21. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
    Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
    Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines.
    Julian-Reynier C; Eisinger F; Moatti JP; Sobol H
    Eur J Hum Genet; 2000 Mar; 8(3):204-8. PubMed ID: 10780786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospectively detected cancer in familial breast/ovarian cancer screening.
    Dørum A; Heimdal K; Løvslett K; Kristensen G; Hansen LJ; Sandvei R; Schiefloe A; Hagen B; Himmelmann A; Jerve F; Shetelig K; Fjaerestad I; Tropé C; Møller P
    Acta Obstet Gynecol Scand; 1999 Nov; 78(10):906-11. PubMed ID: 10577622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
    Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
    Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the understanding of risk factors for ovarian cancer.
    Bandera CA
    J Reprod Med; 2005 Jun; 50(6):399-406. PubMed ID: 16050564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Familial ovarian cancer syndrome].
    Bösze P
    Orv Hetil; 1994 Feb; 135(9):459-64. PubMed ID: 8139849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Genetic predisposition and ovarian cancer].
    Coupier I; Gauthier-Villars M; This P; Stoppa-Lyonnet D
    Rev Prat; 2004 Oct; 54(16):1757-62. PubMed ID: 15630879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognosis and prognostic factor analysis epithelial ovarian cancer].
    Wen H; Sun W; Guo Y
    Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):159-62. PubMed ID: 9596891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial ovarian cancer.
    Elit L
    Can Fam Physician; 2001 Apr; 47():778-84. PubMed ID: 11340759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction.
    Swisher EM; Babb S; Whelan A; Mutch DG; Rader JS
    J Reprod Med; 2001 Feb; 46(2):87-94. PubMed ID: 11255821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serous carcinoma of the peritoneum after oophorectomy.
    Weber AM; Hewett WJ; Gajewski WH; Curry SL
    Obstet Gynecol; 1992 Sep; 80(3 Pt 2):558-60. PubMed ID: 1495737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of breast and ovarian cancer in families with BRCA mutations.
    Vasen HF; Tesfay E; Boonstra H; Mourits MJ; Rutgers E; Verheyen R; Oosterwijk J; Beex L
    Eur J Cancer; 2005 Mar; 41(4):549-54. PubMed ID: 15737559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinicalpathological characteristics of Lynch syndrome related epithelial ovarian cancer].
    Ma XG; Wang YM; Xue FX; Zhang HY; Sheng HN; Qi Z; Liu GY
    Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):201-4. PubMed ID: 22781072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical study of hereditary ovarian cancer syndrome in Shandong province, East China.
    Sheng X; Zhong Y; Lu C; Peng J; Yu H; Guo J
    Int J Gynaecol Obstet; 2018 May; 141(2):234-239. PubMed ID: 29359324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age at onset of ovarian cancer in women with a strong family history of ovarian cancer.
    Goldberg JM; Piver MS; Jishi MF; Blumenson L
    Gynecol Oncol; 1997 Jul; 66(1):3-9. PubMed ID: 9234912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary ovarian cancer. Pedigree studies, Part II.
    Lynch HT; Conway T; Lynch J
    Cancer Genet Cytogenet; 1991 Jun; 53(2):161-83. PubMed ID: 2065292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Familial incidence of ovarian cancer].
    Hengrave G; De Grandi P
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(7):863-71. PubMed ID: 3543103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.